Astex Pharmaceuticals to Present AT26893 at EASL
News Apr 16, 2012
Astex Pharmaceuticals, Inc. has announced that it will present data on AT26893, a novel, first-in-class, direct acting antiviral agent (DAA) against Hepatitis C Virus (HCV) at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL): The International Liver Congress™, April 18 to 22, 2012 in Barcelona, Spain.
The following presentations are scheduled for Friday, April 20th from 12:30 to 2:00 pm during the poster session: Viral Hepatitis C: Experimental (virology)
• Abstract No. 19057: Fragment based discovery and cellular validation of a novel allosteric binding site on the full length HCV NS3/4a enzyme.
• Abstract No. 19064: Pre-clinical characterization of a novel allosteric inhibitor of the HCV full length NS3/4a protein.
The NS3 protein is essential for viral replication and represents a validated HCV therapeutic target.
Astex has used its fragment-based drug discovery approach, Pyramid™, to discover and target a novel allosteric binding site on the full length HCV NS3 protease - helicase enzyme.
Compounds binding at this site have a novel mode of action and a different resistance profile compared to NS3 active-site protease inhibitors and these data will be presented at EASL.
Astex scientists will also present data on the characterization of AT26893 that has entered formal preclinical development in preparation for an IND filing.
This research program, which has been supported with £2 million of funding from the Wellcome Trust Seeding Drug Discovery initiative, is wholly owned by Astex Pharmaceuticals.
Animal venoms are the subject of study at research center based at the Butantan Institute in São Paulo. But in this case, the idea is not to find antidotes, but rather to use the properties of the venoms themselves to identify molecular targets of diseases and, armed with that knowledge, develop new compounds that can be used as medicines.